Aclaris Therapeutics Inc. (NASDAQ: ACRS) stock closed at 18 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 457.51K shares and market capitalization of 1.18B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 60 people. Aclaris Therapeutics Inc. CEO is Neal Walker.

The one-year performance of Aclaris Therapeutics Inc. stock is 23.29%, while year-to-date (YTD) performance is 23.8%. ACRS stock has a five-year performance of -33.26%. Its 52-week range is between 9.26 and 19.97, which gives ACRS stock a 52-week price range ratio of 78.34%

Aclaris Therapeutics Inc. currently has a PE ratio of -11.10, a price-to-book (PB) ratio of 5.63, a price-to-sale (PS) ratio of 217.51, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -42.70%, a ROC of -55.07% and a ROE of -56.53%. The company’s profit margin is -%, its EBITDA margin is -1 127.20%, and its revenue ttm is $4.61 Million , which makes it $0.07 revenue per share.

Of the last four earnings reports from Aclaris Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.36 for the next earnings report. Aclaris Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aclaris Therapeutics Inc. is Strong Buy (1), with a target price of $34.8, which is +97.17% compared to the current price. The earnings rating for Aclaris Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aclaris Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aclaris Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 30.39, ATR14 : 1.23, CCI20 : 264.01, Chaikin Money Flow : 0.15, MACD : 0.45, Money Flow Index : 53.23, ROC : 13.21, RSI : 52.10, STOCH (14,3) : 88.57, STOCH RSI : 1.00, UO : 62.88, Williams %R : -11.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aclaris Therapeutics Inc. in the last 12-months were: Anand Mehra (Option Excercise at a value of $0), Andrew Kenneth Williams Powell (Option Excercise at a value of $0), Andrew N. Schiff (Option Excercise at a value of $0), Andrew N. Schiff (Sold 19 565 shares of value $296 269 ), Bryan M. Reasons (Option Excercise at a value of $0), Christopher Molineaux (Option Excercise at a value of $0), Frank Ruffo (Option Excercise at a value of $0), Frank Ruffo (Sold 12 823 shares of value $199 335 ), Joseph Monahan (Option Excercise at a value of $0), Joseph Monahan (Sold 57 165 shares of value $915 101 ), Kamil Ali-Jackson (Option Excercise at a value of $0), Maxine Gowen (Option Excercise at a value of $0), Neal Walker (Option Excercise at a value of $0), Neal Walker (Sold 126 303 shares of value $1 956 746 ), Vincent J. Milano (Option Excercise at a value of $0), William D. Humphries (Option Excercise at a value of $0)